{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Nalbuphine",
    "query": {
      "condition": "Nalbuphine"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 13,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Nalbuphine&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T12:07:56.883Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02143973",
      "title": "Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Uremic Pruritus",
        "Pruritus"
      ],
      "interventions": [
        {
          "name": "nalbuphine HCl ER",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Trevi Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 167,
      "start_date": "2014-09",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2025-05-21",
      "last_synced_at": "2026-06-26T12:07:56.883Z",
      "location_count": 35,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 29 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Pine Bluff",
          "state": "Arkansas"
        },
        {
          "city": "Azusa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02143973"
    },
    {
      "nct_id": "NCT00716807",
      "title": "Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Temporomandibular Joint Dysfunction Syndrome",
        "Burning Mouth Syndrome"
      ],
      "interventions": [
        {
          "name": "nalbuphine plus naloxone",
          "type": "DRUG"
        },
        {
          "name": "nalbuphine plus placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2008-01",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2016-05-20",
      "last_synced_at": "2026-06-26T12:07:56.883Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00716807"
    },
    {
      "nct_id": "NCT00947284",
      "title": "Effect of Nalbuphine and Naloxone on Experimentally Induced Skin Sensitivity",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "nalbuphine plus naloxone",
          "type": "DRUG"
        },
        {
          "name": "nalbuphine plus saline",
          "type": "DRUG"
        },
        {
          "name": "naloxone plus saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 3,
      "start_date": "2010-01",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2016-05-20",
      "last_synced_at": "2026-06-26T12:07:56.883Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00947284"
    },
    {
      "nct_id": "NCT01488149",
      "title": "Intrapartum Epidural Fentanyl and Breast-feeding in the Immediate Postpartum Period: a Prospective Cohort Study",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Maternal Anaesthesia and Analgesia Affecting Fetus or Newborn",
        "Breast Feeding",
        "Fentanyl",
        "Bupivacaine",
        "Nalbuphine"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University Hospitals Cleveland Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2012-02",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2022-04-18",
      "last_synced_at": "2026-06-26T12:07:56.883Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01488149"
    },
    {
      "nct_id": "NCT07487740",
      "title": "A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "NAL ER",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Trevi Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 60,
      "start_date": "2026-02-27",
      "completion_date": "2026-04",
      "has_results": false,
      "last_update_posted_date": "2026-03-23",
      "last_synced_at": "2026-06-26T12:07:56.883Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07487740"
    },
    {
      "nct_id": "NCT02143648",
      "title": "Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Uremic Pruritus",
        "Pruritus"
      ],
      "interventions": [
        {
          "name": "nalbuphine HCl ER tablets 60 mg BID",
          "type": "DRUG"
        },
        {
          "name": "nalbuphine HCl ER tablets 120mg BID",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablets BID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Trevi Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 373,
      "start_date": "2014-06",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2025-05-21",
      "last_synced_at": "2026-06-26T12:07:56.883Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 35 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Pine Bluff",
          "state": "Arkansas"
        },
        {
          "city": "Azusa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02143648"
    },
    {
      "nct_id": "NCT03497975",
      "title": "PRISM Study-Pruritus Relief Through Itch Scratch Modulation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Prurigo Nodularis"
      ],
      "interventions": [
        {
          "name": "Nalbuphine ER Tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo Tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Trevi Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 353,
      "start_date": "2018-08-07",
      "completion_date": "2023-02-24",
      "has_results": true,
      "last_update_posted_date": "2025-06-24",
      "last_synced_at": "2026-06-26T12:07:56.883Z",
      "location_count": 36,
      "location_summary": "Phoenix, Arizona • Fremont, California • Laguna Niguel, California + 32 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Laguna Niguel",
          "state": "California"
        },
        {
          "city": "North Hollywood",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03497975"
    },
    {
      "nct_id": "NCT02174419",
      "title": "Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Prurigo Nodularis",
        "Nodularis Prurigo",
        "Prurigo",
        "Pruritus"
      ],
      "interventions": [
        {
          "name": "nalbuphine HCl ER tablets 90 mg BID",
          "type": "DRUG"
        },
        {
          "name": "nalbuphine HCl ER tablets 180 mg BID",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablets BID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Trevi Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 62,
      "start_date": "2015-03",
      "completion_date": "2016-08",
      "has_results": true,
      "last_update_posted_date": "2025-05-21",
      "last_synced_at": "2026-06-26T12:07:56.883Z",
      "location_count": 2,
      "location_summary": "Cleveland, Ohio • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02174419"
    },
    {
      "nct_id": "NCT04256434",
      "title": "A Bioavailability Study of NALDEBAIN ER Injection and Nalbuphine Injection in Healthy Volunteers.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Health"
      ],
      "interventions": [
        {
          "name": "Dinalbuphine sebacate",
          "type": "DRUG"
        },
        {
          "name": "Nalbuphine HCl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lumosa Therapeutics Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2020-01-31",
      "completion_date": "2020-05-29",
      "has_results": false,
      "last_update_posted_date": "2021-11-19",
      "last_synced_at": "2026-06-26T12:07:56.883Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04256434"
    },
    {
      "nct_id": "NCT07015398",
      "title": "A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "NAL ER",
          "type": "DRUG"
        },
        {
          "name": "Pirfenidone",
          "type": "DRUG"
        },
        {
          "name": "Nintedanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Trevi Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 132,
      "start_date": "2025-06-30",
      "completion_date": "2025-09-26",
      "has_results": false,
      "last_update_posted_date": "2025-10-10",
      "last_synced_at": "2026-06-26T12:07:56.883Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07015398"
    }
  ]
}